Fingolimod 0.5 mg vs placebo
Outcomes at 24 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
12 questions · 12 findings · 1 reviews
No studies found 2 · 16.7%GRADE not reported 0 · 0%Very low 1 · 8.3%Low 3 · 25%Moderate 6 · 50%High 0 · 0%
Fingolimod 0.5 mg vs interferon beta‐1a
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
- RR 1.51 [0.81, 2.8]1 study · 860 participantsModerate
Fingolimod 0.5 mg vs interferon beta‐1a
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
- Rate ratio 0.48 [0.34, 0.7]1 study · 860 participantsModerate
Fingolimod 0.5 mg vs interferon beta‐1a
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
- RR 1.12 [1.05, 1.19]1 study · 728 participantsModerate
Fingolimod 0.5 mg vs placebo
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.44 [1.28, 1.63]2 studies · 1556 participantsModerate
Fingolimod 0.5 mg vs placebo
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from disability worsening compared with placebo (low certainty).
1 finding from 1 review
- RR 1.07 [1.02, 1.11]2 studies · 1556 participantsLow
Fingolimod 0.5 mg vs placebo
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.42 [0.89, 2.25]2 studies · 1556 participantsVery low
Fingolimod 0.5 mg vs placebo
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with placebo (moderate certainty).
1 finding from 1 review
- Rate ratio 0.5 [0.4, 0.62]2 studies · 1556 participantsModerate
Fingolimod 0.5 mg vs placebo
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from MRI gadolinium‐enhancing lesions compared with placebo (low certainty).
1 finding from 1 review
- RR 1.36 [1.27, 1.45]2 studies · 1226 participantsLow
Fingolimod 0.5 mg vs interferon beta‐1a
Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Fingolimod 0.5 mg vs interferon beta‐1a
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
- RR 1.18 [1.09, 1.27]1 study · 860 participantsModerate
Fingolimod 0.5 mg vs interferon beta‐1a
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).
1 finding from 1 review
- RR 1.02 [0.99, 1.06]1 study · 860 participantsLow